Strong Q2 prompts Qiagen guidance hike
This article was originally published in Clinica
Dutch diagnostics firm Qiagen has raised its revenue and EPS guidance for fiscal 2009 after posting healthy second-quarter results. The company upped revenue expectations for the full year from $920-970m to $930-970m and EPS forecasts from $0.88-0.94 to $0.90-$0.94 per share. Venlo-based Qiagen said that robust market demand and solid economic trends within the diagnostic sector helped to boost sales. Revenue for the period was $240.2m, up 10% from Q2 2008. Increased sales of the firm’s HPV screening products, KRAS diagnostics and H1N1 tests helped grow the top line. Qiagen’s net income also benefited from the stronger sales and reached $48.3m compared to $40.4m in the same period last year.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals